Comparative Pharmacology
Head-to-head clinical analysis: EYSUVIS versus INFLAMASE FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EYSUVIS versus INFLAMASE FORTE.
EYSUVIS vs INFLAMASE FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eysuvis (loteprednol etabonate ophthalmic suspension) is a corticosteroid that works by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes, thereby reducing inflammation.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
1 drop in each eye twice daily (approximately 12 hours apart) for 4 weeks.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
None Documented
None Documented
Approximately 2-4 hours for loteprednol etabonate; clinical effect correlates with dosing interval (e.g., 4 times daily).
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal (90-95% as unchanged drug and metabolites); minor biliary/fecal (<5%).
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid